Amryt announce highly positive results for sufferers of bad cholesterol

A mryt Pharmaceuticals is a biopharmaceutical company which focuses on the rare diseases and oddities in the medical world. The company tries to transform the lives of such patients through innovative treatments, and make life easier for them. One such project taken up by the company was the Lojuxta treatment, which targets bad cholesterol. The study yielded excellent results, and hence, the Irish pharmaceutical giant has good news for people suffering from bad cholesterol. They’ve announced the results of a long-term study into a rare, life threatening disease Homozygous Familial Hypercholesterolaemia ("HoFH") and its treatment using Lojuxta, and they’re reportedly very positive. Lojuxta was in-licensed by Amryt as a treatment for adults with HoFH, and after a study lasting 5.7 years, which followed patients and analysed the results of them taking the treatment over the period, showed that Lojuxta is highly effective in lowering the levels of bad cholesterol. The treatment reportedly lowered the levels of LDL cholesterol, better known as bad cholesterol to levels tolerable for good health. The 5.7 year study also showed no noticeable side-effects of the treatment and it resulted in no new safety signals. This is very good news because bad cholesterol not only makes you fat, but it leaves you extremely vulnerable to cardiovascular diseases, and the Lojuxta treatment, given with other lipid-lowering therapies has shown positive outcomes.